z-logo
open-access-imgOpen Access
Results of antiviral treatment of patients with chronic hepatitis C: experience of Poznan centre
Author(s) -
Maciej Bura,
Arleta KowalaPiaskowska,
Agnieszka Adamek,
Aleksandra Bura,
Arkadiusz Czajka,
Katarzyna Hryckiewicz,
Iwona Bereszyńska,
Iwona MozerLisewska
Publication year - 2012
Publication title -
postępy higieny i medycyny doświadczalnej
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.275
H-Index - 34
eISSN - 1732-2693
pISSN - 0032-5449
DOI - 10.5604/17322693.1000332
Subject(s) - medicine , ribavirin , viremia , hepatocellular carcinoma , hepatitis c virus , gastroenterology , cirrhosis , population , pegylated interferon , hepatitis c , viral load , liver biopsy , immunology , virus , biopsy , environmental health
Hepatitis C virus (HCV) infection in Poland affects approximately 750 thousand persons. The prevention of cirrhosis and hepatocellular carcinoma, of which approximately 20% of patients with chronic hepatitis C virus are at risk, aims at eradication of the virus by applying antiviral treatment with pegylated interferon alpha with ribavirin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here